Skip to contents

Daniel Hal Solomon, MD, MPH
Associate Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Rheumatology, Immunology
75 Francis Street
Boston, MA 02115

Research Email:

Edit Profile

Research Narrative:
            Dr. Solomon is a population scientist focusing on the epidemiology and health services of rheumatic disease. He serves as the Chief of the Section of Clinical Sciences in the Division of Rheumatology at BWH. His research work is primarily funded by the NIH, AHRQ, and foundations. He has served major roles at the American College of Rheumatology and within the osteoporosis community as well. 
His achievements in population science research focuses on three areas. First, he has been a leading investigator on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs). He has been the first author on 12 original articles in this area, has several industry-sponsored grants and one AHRQ sponsored grant in this area, and led the American College of Rheumatology Blue Ribbon Panel to set recommendations for NSAIDs. He has given over 15 invited talks on this topic and currently serve on the Executive Committee of the largest randomized controlled trial on the cardiovascular safety of NSAIDs and selective COX-2 inhibitors.
 Second, he has focused much of his research on cardiovascular manifestations of rheumatoid arthritis and its treatment. He completed one NIH grant on this topic and have another current NIH grant to study insulin and glucose metabolism in rheumatoid arthritis. He is the first author on 5 publications describing the epidemiology of cardiovascular disease in patients with rheumatoid arthritis and has given 8 invited lectures in this area.
Finally, he has helped define standards for osteoporosis care improvement. He has received two NIH grants in this area. A current NIH funded study is a large-scale adherence improvement trial for osteoporosis medications. He has first authored 8 original articles in this area and given 10 invited lectures on osteoporosis improvement. He serves on the steering committee of the National Action Plan for Bone Health, focusing on methods to improve dissemination of proven improvement methods, as well as on the American Orthopaedic Association’s Own the Bone Program.
               He teaches and mentors primarily in rheumatic disease epidemiology and pharmacoepidemiology.   He has mentored over 25 fellows and trainees and have a K24 award from NIH with 25% effort devoted to research training and mentoring. He developed and directed a course in clinical research for rheumatologists. As well, he teaches residents in the BWH Department of Medicine’s lecture series and journal club.

Investigative Interests:  drug safety and effectiveness

Harvard School of Public Health, 1998, MPH
Yale School of Medicine, 1992, MD

American College of Rheumatology Young Investigator Award
NIH Mentoring Award
Chief, Section of Clinical Sciences, Rheumatology
Co-Director, Patient-Centered Research Center

Publications (Pulled from Harvard Catalyst Profiles):

1. Zhao SS, Yoshida K, Jones GT, Hughes DM, Duffield SJ, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, Goodson NJ. Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2019 Jul 22; 21(1):177.

2. Li D, Yoshida K, Feldman CH, Speyer C, Barbhaiya M, Guan H, Solomon DH, Everett BM, Costenbader KH. Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2019 Jul 18.

3. Yu Z, Kim SC, Vanni K, Huang J, Desai R, Murphy SN, Solomon DH, Liao KP. Correction to: Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Res Ther. 2019 Jul 08; 21(1):170.

4. Kim SC, Jin Y, Lee YC, Lii J, Franklin PD, Solomon DH, Franklin JM, Katz JN, Desai RJ. Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. JAMA Netw Open. 2019 Jul 03; 2(7):e198061.

5. Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH. Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use. J Clin Endocrinol Metab. 2019 Jul 02.

6. Feldman CH, Costenbader KH, Solomon DH, Subramanian SV, Kawachi I. Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study. Arthritis Care Res (Hoboken). 2019 Jul; 71(7):903-913.

7. Solomon DH, Ruppert K, Kazlauskaite R, Finkelstein JS, Habel LA. Blood pressure lowering medication initiation and fracture risk: a SWAN pharmacoepidemiology study. Arch Osteoporos. 2019 Jun 28; 14(1):73.

8. Jin Y, Solomon DH, Franklin PD, Lee YC, Lii J, Katz JN, Kim SC. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthritis Cartilage. 2019 Jun 26.

9. Solomon DH, Shao M, Wolski K, Nissen S, Husni ME, Paynter N. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis Rheumatol. 2019 Aug; 71(8):1225-1231.

10. Lalani R, Lyu H, Vanni K, Solomon DH. Low Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2019 May 31.